BioCurex, Inc.(fka BOCX)

[20cbocx]

Consider the following statements are true:
1. abt has spent considerable money adapting recaf to their equipment
2. It will cost considerable additional money to conduct the required studies to get fda approval
3. Assuming fda approval it will cost considerable money to train their sales staff to sell the test to doctors and labs.
4. They(abt)are aware of bocx's work on a point of care test
5. This "poc" test is not part of their (abt) license
6. The "poc" test could make abt's test obsolete
Why would abt spend another dime to bring their recaf test to market? Help me here. I want to believe abt will proceed.